This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Consider it a testament to the ubiquity and flexibility of the endocannabinoid system: we can inhale medicinal cannabinoids via combustion or vaporization; ingest them via food or drink; and absorb them directly through the skin, the bodys largest organ. This latter category is broader and more complex than many of us give it credit for.
The daily use of cannabis by patients with chronic pain conditions is associated with prolonged improvements in pain management and subjects’ overall quality of life, as well as sustained reductions in the use of opioids, according to longitudinal data published in the journal Pain Medicine.
Importation, cultivation, production, and other activities conducted for medicinal and scientific purposes are lawful under federal Australian law when the necessary licenses and permits have been obtained. This Q&A focuses primarily on medicinal cannabis (containing higher THC). Australia Cannabis Q&A A.
The administration of herbal cannabis is safe and effective in patients diagnosed with fibromyalgia, according to clinical data published this month in the Journal of Clinical Medicine. Eight-one percent of subjects reported “at least moderate improvement in their condition … without experiencing serious adverse events.”
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.
179 : The VA Medicinal Cannabis Research Act of 2019 to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans. Furthermore, twenty-two percent of respondents said they themselves “use cannabis to treat a mental or physical condition.”
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
When you walk into a hardware store, pharmacy, or even a liquor store, if you don’t know exactly what product will meet your needs there’s someone educated enough to point you to the right product and the data to back up that recommendation, says Tyler Dautrich, COO of Releaf. Edited and mixed by Michael Schaeffer Omer-Man.
1 When we invited Cannigma readers to try Slumber’s Deep Zzzs gummies for sleep, we were particularly interested in digging into the data on sleep quality – not just total sleep time. 2 While the data collection effort did not include a control group, the prime findings were found to be statistically significant.
According to research by real estate data company, Clever , property values rose by $17,113 more in states where recreational cannabis is legal, compared to states where it’s illegal or just legal at the medicinal level. Clever combined data from Zillow, the U.S. This Data Says So appeared first on Green Market Report.
Those suffering from chronic pain report significant improvements in health following the passage of medical cannabis access laws, according to data published in the journal Forum for Health Economics & Policy. Among state-licensed medical cannabis registrants, two out of three report consuming cannabis to mitigate pain conditions.
In this article, we’ll delve into the newest research findings and explore how medicinal cannabis could revolutionize cancer pain management and reduce reliance on opioids and other medications. of the patients reported pain as their primary motivation for obtaining a medicinal cannabis prescription. Interestingly, 72.5%
One gastrointestinal condition long associated with self-medication through cannabis is inflammatory bowel disease (IBD). IBD in Puerto Rico In 2016, the government of Puerto Rico legalized medicinal cannabis for a relatively short list of specific conditions, including Crohn’s disease.
Of the 1,276 participants, 524 adult patients and 284 adult caregivers of children or dependent adults, all self-reported using cannabis for medicinal purposes. All of the participants self-reported that they or their dependent patient had a diagnosed health condition at the time of the baseline assessment.
HB1445/SB1235, unfortunately, didn’t provide a framework for cultivating or distributing medicines, so patients had to get their cannabis from another state (a no-no under the US Department of Justice’s now-rescinded guidelines ). The 2017 expansion of Virginia’s medical marijuana law got rid of qualifying conditions.
The groundbreaking study conducted by New Frontier Data surveyed over 3,000 adult Americans to show people from all age groups and demographics in the U.S. 73% of medical cannabis users said that they used cannabis as a substitute for other medicines, while 41% used it as a replacement for over-the-counter painkillers.
They evaluate data, which is now available thanks to the efforts of the cannabis policy reform movement, and try to provide answers, especially to those who need them most, namely, medical patients. It seems as though research on cannabis and cannabinoids is taking such large strides that it even surpasses research growth in other fields.
The study was developed by People Science , a tech-enabled science company that is focused on connecting “health minded people, research scientists, and healthcare providers in an effort to unlock the potential of alternative medicines,” according to People Science. One of the tools to try to tackle sleep and wellness”.
His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz and colleagues have published a paper summarizing ORR data from individuals with epilepsy in the medical journal Epilepsy & Behavior.
Cannabidiol ( CBD ), the non-psychoactive cannabinoid praised for medicinal powers like reducing the severity and frequency of seizures in children suffering from rare and otherwise untreatable forms of epilepsy, may not be the most medically beneficial molecule found in cannabis, according to new data. Data Tracking.
Context of the Medicinal Cannabis Situation. Under the regulations, no intermediaries are allowed to sell medicinal cannabis to patients. The Canadian medicinal cannabis regime was established in the context of illegal cannabis use. It allows patients to have access to medicinal cannabis without danger of being criminalized.
Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Parkinson’s disease and cannabis.
This efficacy translates to better medicine and better treatments for patients. Patients should speak with their certified medical marijuana physician to determine which strains and methods of consumption are most appropriate for their medical conditions. Over 100 cannabis-based Terpenes have been discovered.
In the article — “Is Marijuana as Safe as We Think?” — writer Malcolm Gladwell focused on a 2017 report by the National Academy of Medicine that examined the scientific evidence of the health effects and therapeutic purposes of cannabis and cannabinoids. In 2017, for example, Washington had 304.5
#image_title By Dr. Fernando Fandio-Sende, LifeCannMD After thirty years practicing medicine and specializing as a Miami cannabis doctor , I’ve had countless conversations with patients who tell me the same thing: “Doctor, I want to try medical marijuana , but I’m scared of getting too high.” hours longer per night.
For an engineer like Rick, who understood the value of evidence and data, it was a revelation. “If you knew what I know about this medicine and the people who need it,” he once said, “you’d do the same thing.” Can it help with other conditions? Something clicked in Rick’s mind.
When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. Transfering nurses’ skills to cannabis medicine. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.
Medical cannabis is more popular than ever before, with 38 states having legalized some form of it for various health conditions. This data aligns with Americans’ rising acceptance of cannabis. The most popular qualifying conditions continue to be chronic pain and PTSD, some of which may be related to the pandemic.
In these three dozen states, from the West Coast to the Midwest to the South and the Northeast, patients use cannabis to treat countless medical conditions and everyday ailments. of patients reported chronic pain as their primary condition, while in Connecticut 70.4% The most common medical conditions. In Colorado, 78.7%
First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.
THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.
She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. CannMed: For what conditions do you think CBG has the most promise? It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research.
More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. of prescriptions were for sleep disorders.
Moreover cannabis has been used medicinally and recreationally for thousands of years. 5 William O’Shaughnessy, a medical doctor who had practiced medicine in british-occupied India, is credited as the first to bring medical cannabis over to Europe. But of course, cannabis is not solely used as medicine.
For all modern medicine can do, many mysteries remain unsolved. Recently published papers — a series of reviews, two human studies, and an animal study — only bolster the case that cannabis can help those suffering from this confounding condition. What is long COVID? Is there really such thing as a “cure” for cancer?
By 2024, the medicinal cannabis market within the United Kingdom is predicted to be worth nearly US$1.3 has emerged as the largest supplier of medicinal cannabis in the world. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. in real terms to £4.97
Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. billion, servicing nearly 340,000 active patients. About RYAH Group, Inc.
GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.
Science and medicine are the basis of Delic’s approach to psychedelic wellness and our experienced and diverse Medical Advisory Board will help ensure our commitment to safety, quality and efficacy of treatments,” said Delic CEO Matt Stang. Chris Ray , PhD : Interventional Pain Physician.
Marijuana may be a lucrative opportunity on the surface, but there are several conditions that could put the industry out of reach for some time. The production of pharmaceutical-grade cannabis is a highly specialised process — it is not as simple as planting a few marijuana seeds, harvesting the crop and turning it into medicine.”.
By engaging individuals across various age groups and demographics, we gather insights into usage patterns, medical conditions, past substance experiences, and more. California was the first state to legalize medicinal cannabis in 1996, right around the time that Gen Z began to enter society.
Results from the third Cannabis as Medicine study. The third Cannabis as Medicine Survey (CAMS20) follows on from CAMS16 and CAMS18, and includes 1,600 people using medical cannabis between September 2020 and January 2021. People using illicit products were more likely to be treating mental health or sleep conditions.
” Kulfas’ presentation began with some hard data, giving an account of the importance of regulating the activity in Argentina. Why does Argentina have the conditions to be an important producer in the cannabis and hemp industry? ley cáñamo argentina. ley cáñamo argentina.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content